The Authors acknowledge the support of all the members of the ALA CRN including principal investigators and nursing coordinators who contributed to timely patient recruitment in the PREDICT study. Both RXDX-106 cell line the PREDICT and CHARIOT studies were sponsored by financial grants received by Roche Australia. Peter Angus, Austin Hospital, Vic.; Stephen Bollipo, John Hunter, NSW; Wendy Cheng, Royal Perth, WA; Geoff Chu, Orange, NSW; Mark Cornwall, Lismore, NSW; Darrell Crawford, Greenslopes, Qld; Greg Dore, St Vincent’s Hospital,

NSW; Mark Douglas, Blacktown, NSW; Jacob George, Westmead Hospital, NSW; Richard Hallinan, Redfern, NSW; Mazhar Haque, Mater Hospital, Qld; Glenn Hawkin, Gosford, NSW; Hugh Jackson, Hobart Hospital, Tas.; Richard Johnson, Royal Adelaide, SA; Ian Kronborg, Western Hospital, Vic.; Alice Lee, Concord Hospital, NSW; Barbara Leggett, Royal Brisbane Hospital, Qld.; Marc Le Mire, Royal Adelaide Hospital, SA; Miriam Levy, Liverpool Hospital, NSW; John Lubel, Box Hill Hospital, Vic.; Gerry MacQuillan, Sir Charles Gairdner Hospital, WA; John Masson, Townsville Hospital, Qld; Geoff McCaughan, Royal Prince Alfred Hospital, NSW; Jenny McDonald, Wollongong, NSW; Bruce McGarity, Bathurst, NSW; Lindsay Mollison, Fremantle Hospital, WA; Amanda Nicoll, Royal Melbourne Trametinib cost Hospital, Vic.; John Ombiga, Cairns, Qld.; George Ostapowicz, Gold Coast Hospital, Qld; Stephen Riordan, Prince of Wales Hospital, NSW; Stuart

Roberts, The Alfred Hospital, Vic; Andrew Sloss, Nambour, Qld; William Sievert, Monash Medical Centre, Vic.; Simone Strasser, Royal Prince Alfred Hospital, NSW; Alex Thompson, St Vincent’s Hospital, Vic; Jon Watson, Geelong Hospital, Vic; Martin Weltman, Nepean Hospital, NSW; John Wenman, Coff’s Harbour, NSW; Alan Wigg, Flinders Hospital, SA; Amany Zekry, St George Hospital, NSW. “
“Aim:  To evaluate the antitumor effects and hepatotoxicity of transcatheter arterial chemoembolization (TACE) with Amoxicillin cisplatin-iodized

oil suspension and emulsion in a rabbit tumor model. Methods:  Transcatheter arterial chemoembolization was performed on 12 rabbits with hepatic VX2 tumors using a cisplatin suspension (1 mg/kg cisplatin and 0.1 mL/kg iodized oil, n = 6) or emulsion (1 mg/kg cisplatin, 0.1 mL/kg of iodized oil, and 0.1 mL/kg saline solution, n = 6). Time series changes in plasma platinum concentration were compared over 24 h. All rabbits were killed at 7 days after TACE, and the growth ratio and residual viable proportion of tumors were calculated on the basis of ultrasonographic and histopathological findings. Hepatotoxicity was also evaluated. Differences between the two groups were statistically assessed with the Mann–Whitney U-test. The animal care committee of our institute approved this study. Results:  Plasma platinum concentrations were significantly higher in the suspension group than in the emulsion group at 0.5–24 h after TACE (P < 0.05). Growth ratios (−24.6 ± 9.98% vs. 21.4 ± 8.